US Omega-3 Supplement Firm Changes Claims On Amarin Challenge, But Not Label Or Company Name

Fish-Oil Based Drug Marketer's Latest Challenge To Omega-3 Claims Is NAD Review

National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.

• Source: Alamy

Amarin Corporation plc argues that an omega-3 supplement marketer should include safety warnings on labels similar to those required for its fish oil-derived drug Vascepa and that the use of “pharma” in the firm’s name is false advertising.

An industry self-regulation group doesn’t agree.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Compliance

More from Policy & Regulation